Accelerated titration and 3 + 3 dose escalation were used in this trial . Six dose groups were preset, including 50 mg，150 mg，400 mg，800 mg，1600 mg， 2400 mg by intravenous infusion.
This phase I, first-in-human, open-label clinical study will evaluate the safety, tolerability, kinetics and preliminary anti-tumor efficacy of intravenous infusion of HLX53 in patients with advanced or metastatic solid tumors or lymphoma for whom there is no standard therapy or no standard therapy available. HLX53 is an Fc fusion protein against TIGIT.